The effect of synbiotic yogurt on non alcoholic fatty liver disease

The effect of synbiotic yogurt consumption on liver echogenicity and markers of liver function in patients with non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017020932417N2

Enrollment

102

Registered

2017-03-12

Start date

2016-07-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: The second intervention group will be consume 300 grams per day conventional yogurt in addition to usual treatment for six months. Intervention 2: The first intervention group will be

Treatment - Other

The second intervention group will be consume 300 grams per day conventional yogurt in addition to usual treatment for six months.

The first intervention group will be consume 300 grams per day synbiotic yogurt in addition to usual treatment for six months.

The control group will receive usual treatment for six months.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: contracting non alcoholic fatty liver disease and age of between 18 and 75. Exclusion criteria: alcohol use; viral hepatitis; hepatocellular carcinoma; other causes of chronic liver disease; diabetes mellitus; untreated hypothyroidism; psychiatric disorder; kidney disease; pregnancy; and lactation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fat free mass. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: BIA, percentage.;Fat mass. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: BIA, percentage.;Hepatic steatosis. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Fasting blood sugar. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Serum Insulin. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Radioimmunoassay, µU/ml.;Alanine Aminotransferase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Aspartate transaminase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Alkaline phosphatase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Gamma Glutamyl transferase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Total antioxidant capacity. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELISA method, µM.;Total oxidant status. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Enzymatic method, µM.;Complement C1q/tumor necrosis factor-a related protein-5. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELISA method, mg.;Glucagon like peptide-2. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELIZA method, pg/ml.;Systolic blood pressure. Timepoint: At wee	—

Measure

Time frame

Fat free mass. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: BIA, percentage.;Fat mass. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: BIA, percentage.;Hepatic steatosis. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Fasting blood sugar. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, mg/dl.;Serum Insulin. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Radioimmunoassay, µU/ml.;Alanine Aminotransferase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Aspartate transaminase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Alkaline phosphatase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Gamma Glutamyl transferase. Timepoint: At weeks 0, 8, 16 and 24. Method of measurement: Enzymatic method, IU/Lit.;Total antioxidant capacity. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELISA method, µM.;Total oxidant status. Timepoint: Before Intervention and six months after Intervention. Method of measurement: Enzymatic method, µM.;Complement C1q/tumor necrosis factor-a related protein-5. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELISA method, mg.;Glucagon like peptide-2. Timepoint: Before Intervention and six months after Intervention. Method of measurement: ELIZA method, pg/ml.;Systolic blood pressure. Timepoint: At wee

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Alizadeh

Urmia University of Medical Sciences

alizadeh.m@umsu.ac.ir+98 44 3275 2375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 6, 2026